Exploring Decentralized Clinical Trials (DCTs) – a new monthly blog series

Welcome to the Decentralized Clinical Trials (DCTs) monthly blog.With patient-centric trial designs becoming a driving force in the drug development industry, we will be doing a series of monthly blogs that look back on recent events which give us insight into designing resilient clinical trials and ensuring study and data continuity. 

Addressing social determinants of health through preventive programs and community partnerships

Labcorp partners with community organizations to increase access to education, healthy foods and preventive healthcare services, such as health screenings, to improve health equity.

Urine drug testing for medication-assisted treatment (MAT)

Treatment professionals agree that monitoring drug use during MAT can be a powerful incentive for abstinence, and it can also help identify OUD relapse.

Using LC-MS/MS to optimize the OECD 456 H295R steroidogenesis assay for sensitive and selective detection

Assessing in vitro steroidogenesis endpoints is an important early step in establishing the endocrine disruptor (ED) potential of your crop protection product. Many regulators worldwide now require this information as part of the registration and approval process; for example, in the E.U., the updated pesticide and biocide directives now requests information on ED potential to be included. OECD test number 456 provides in vitro mechanistic information about the impact of a chemical on steroidogenesis and this can determine if subsequent in vivo studies are needed. A reliable, sensitive and selective analytic methodology for measuring steroid hormones is, therefore, a prerequisite for success with OECD 456 – read on to find out how such a method has been optimized by using high-end technology platforms.

Business continuity: how robust is your patient support disaster relief plan?

To drive speed to therapy, reduce financial burdens and empower patient engagement, a Patient Support Services Call Center provides myriad support services that stakeholders depend upon. For pharmaceutical manufacturers, these services have gone from “nice to have” to “must-have,” driven by the growth of specialty pharmaceuticals. The complexity of treatment, advances in genetic and diagnostic testing and the high cost of specialty products require highly trained personnel, operation efficiencies and the flexibility to scale in lock-step with a product’s life-cycle stage or market conditions.

Five critical success factors for navigating EOGRTS complexity and smoothing the progress of your chemical registration

The EOGRTS or OECD 443 is a scientifically and logistically complex study. Five critical success factors can help you overcome the complexities to achieve DART success.

How to answer basic physical chemical questions for your chemical and agrochemical substances when test guidance changes and as regulatory standards evolve

Although most physiochemical endpoints are standard for crop and chemical active substances, selection of the right test method to assess them is critical. This blog reviews some standard endpoints and looks at the tests used, in the light of changing regulatory expectations and revised test methodologies for difficult substances.